Article in Blood, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors.
Yu WangDepartment of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI.ORCID 0000-0002-8946-8990
Greggory MyersDepartment of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI.ORCID 0000-0003-2810-8091
Lei YuDepartment of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI.ORCID 0009-0005-4897-1265
Kaiwen DengDepartment of Computational and Medical Bioinformatics, University of Michigan Medical School, Ann Arbor, MI.ORCID 0000-0003-0365-6278
Ginette Balbin-CuestaDivision of Hematology/Oncology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI.ORCID 0000-0002-1062-6774
Sharon A SinghDivision of Hematology/Oncology, Department of Pediatrics, University of Michigan Medical School, Ann Arbor, MI.ORCID 0000-0001-6471-3171
Yuanfang GuanDepartment of Computational and Medical Bioinformatics, University of Michigan Medical School, Ann Arbor, MI.
Rami KhoriatyDepartment of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI.ORCID 0000-0003-2539-5953
James Douglas EngelDepartment of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI.ORCID 0000-0001-9593-1825
Funding
MICHIGAN MEDICAL SCIENTIST TRAINING PROGRAMT32GM007863 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI COLLINS, KATHLEEN L. · 1985 to 2024
$38.3M
Targeting Enzymatic Regulation of Fetal Hemoglobin RepressionP01HL146372 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ENGEL, JAMES DOUGLAS · 2019 to 2023
$10.9M
Stem Cell and Transplantation BiologyU54DK106829 · NIDDK · FRED HUTCHINSON CANCER RESEARCH CENTER · PI DEREK L STIREWALT · 2015 to 2026
$9.1M
University of Michigan Postbaccalaureate Research Education Program (UM PREP)R25GM086262 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ALLEN, BENJAMIN · 2009 to 2024
$6.1M
The molecular pathophysiology of the congenital dyserythropoietic anemiasR01HL148333 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Rami Khoriaty · 2019 to 2026
$4.6M
Cellular and Molecular Biology at MichiganT32GM145470 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI John Chadwick Brenner · 2022 to 2026
$4.1M
Machine Learning for Drug Response PredictionR35GM133346 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Yuanfang Guan · 2019 to 2026
$3.2M
The regulation of thrombopoietin levelsR01HL157062 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KHORIATY, RAMI · 2021 to 2024
$2.1M
University of Michigan Kidney, Urology and Hematology Research Training NetworkU2CDK129445 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BENJAMIN L MARGOLIS · 2022 to 2026
$2.0M
The role of Rpl5 haploinsufficiency in hematopoietic stem/progenitor cell function in Diamond Blackfan anemiaK08DK127013 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Sharon A Singh · 2022 to 2026
abstractNuclear receptor TR4 (NR2C2) was previously shown to bind to the -117 position of the γ-globin gene promoters in vitro, which overlaps the more recently described BCL11 transcription factor A (BCL11A) binding site. The role of TR4 in human γ-globin gene repression has not been extensively characterized in vivo, whereas any relationship between TR4 and BCL11A regulation through the γ-globin promoters is unclear at present. We show here that TR4 and BCL11A competitively bind in vitro to distinct, overlapping sequences, including positions overlapping -117 of the γ-globin promoter. We found that TR4 represses γ-globin transcription and fetal hemoglobin accumulation in vivo in a BCL11A-independent manner. Finally, examination of the chromatin occupancy of TR4 within the β-globin locus, compared with BCL11A, shows that both bind avidly to the locus control region and other sites, but only BCL11A binds to the γ-globin promoters at statistically significant frequency. These data resolve an important discrepancy in the literature and, thus, clarify possible approaches to the treatment of sickle cell disease and β-thalassaemia.
Indexed as
Carrier Proteinsgamma-GlobinsNuclear ProteinsPromoter Regions, GeneticRepressor ProteinsTranscription, GeneticAnimalsbeta-GlobinsBinding SitesChromatinFetal HemoglobinGene Expression RegulationHumansK562 CellsMiceNuclear Receptor Subfamily 2, Group C, Member 2BCL11A protein, humanbeta-GlobinsCarrier ProteinsChromatinFetal Hemoglobingamma-GlobinsNuclear ProteinsNuclear Receptor Subfamily 2, Group C, Member 2Repressor Proteins
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
TR4 and BCL11A repress γ-globin transcription via independent mechanisms. · full record | OpenQuestion